Download Full Text (288 KB)


Pneumonia (PNA) is a leading cause of infectious-related hospitalization in United States. Close to a third of patients receive inappropriate anti-methicillin-resistant Staphylococcus aureus (MRSA) coverage for pneumonia. This can increase length of stay, health care cost, and cause harm to patients. MRSA nasal swab (via MRSA culture or PCR) can aid in ruling out MRSA pneumonia, facilitating the reduction of anti-MRSA treatment. In 2018, via delegated authority, pharmacists were able to order MRSA nasal culture in patients with community-acquired PNA (CAP). AIM: Outline a comprehensive, evidence-driven, multi-year (2018-2023), interdisciplinary, and cost-conscious system-wide strategies aimed at enhancing quality of care by optimizing the use of diagnostics and anti-MRSA antibiotics.

Publication Date



Henry Ford Health


Detroit, Michigan


Quality Expo, posters, poster competition

Project #15: A Tale of Two Nasal Swabs: Impact of Process Improvement in Testing for MRSA Pneumonia



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.